Oddity Tech (ODD) Q2 2026 Earnings Call Transcript

ODDITY reported Q2 net revenue of $181 million, down 25% year over year, as an algorithm dislocation at its largest advertising partner drove first-order revenue down about 40%, repeat revenue down 20%, and gross margin down 360bps to 68.7%. Adjusted EBITDA of $13 million exceeded the $8 million-$10 million outlook, while Q3 guidance calls for a narrower 5% revenue decline and $18 million-$20 million of adjusted EBITDA; full-year revenue is still expected to decline about 19%. SpoiledChild is projected to grow at least 35% to nearly $350 million in 2026 and METHODIQ is outperforming its initial launch expectations, partly offsetting IL MAKIAGE pressure. The company ended the quarter with $561 million in cash and investments, repurchased $163 million of shares year to date, reducing shares outstanding by about 20%.

Analysis

ODD’s core risk is not merely a temporary marketing-cost spike; it exposes a concentrated dependency on one performance-advertising ecosystem. The damage propagates with a lag because lost new-customer cohorts reduce future repeat revenue, so a Q3 improvement in reported revenue does not establish that customer economics have normalized. A durable rerating requires evidence that incremental acquisition contribution margin and first-order volume recover simultaneously, rather than improvement driven by harvesting the existing base or reduced spending.

The aggressive capital return creates a meaningful per-share cushion: a 20% reduction in diluted share count and discounted debt retirement can amplify any earnings recovery. But it also raises the hurdle for management: deploying scarce capital into buybacks while funding METHODIQ, international expansion, and a new brand could obscure whether the legacy business is generating attractive organic returns. Excess inventory is a further risk to gross margin if IL MAKIAGE demand does not normalize before products require promotional clearance or write-downs.

The non-obvious upside is that the disruption may force channel diversification and a higher immediate-purchase mix, improving attribution quality and reducing future dependence on trial conversion. Conversely, expansion into prescription metabolic and peptide therapies moves ODD into a far more regulated and crowded field, competing for consumer attention with HIMS, AMWL and private telehealth platforms; this is strategically attractive but unlikely to be margin-accretive in the next 6-12 months. Consensus may over-credit the Q3 cadence: management explicitly lacks visibility on Q4 spend allocation, making the recovery path more execution-dependent than the headline sequential improvement suggests.

Key Decisions for Investors

• Maintain ODD as a watch-list long, not an immediate recovery purchase. Enter only after evidence of two consecutive months of improving first-order growth and stabilized acquisition economics; the next earnings release is the key 1-3 month catalyst.
• For existing ODD exposure, use a tight thesis stop if Q4 guidance implies further first-order deterioration, gross margin falls below the high-60% long-term framework, or management raises inventory-related charges. Those outcomes would indicate a demand/monetization issue rather than an ad-platform remediation.
• Express near-term skepticism via a small ODD short or underweight versus ELF over the next earnings cycle, subject to valuation and borrow confirmation. ODD faces idiosyncratic customer-acquisition uncertainty while a profitable beauty peer offers a cleaner category-demand benchmark; cover if ODD demonstrates normalized first-order growth and CPA recovery.
• Monitor META advertising-product changes and ODD’s disclosed mix of non-primary channels. A verified shift of acquisition volume without deterioration in payback would be the strongest structural catalyst for multiple expansion over 6-18 months.